NHS Weight Loss Drug: Doctor Warns Incentives Won’t Fix Access Issues
Access to new weight loss medications on the National Health Service (NHS) in England remains uneven, with significant challenges hindering widespread availability despite recent efforts to improve uptake. While the drugs, including tirzepatide (Mounjaro) and semaglutide (Wegovy), have shown promise in clinical trials and are approved for use in certain patients, a combination of logistical hurdles, funding constraints, and workforce pressures are limiting their reach.
Mounjaro, a diabetes drug also effective for weight loss, became available via GPs in , with an initial plan to treat approximately 220,000 patients over three years. However, data from revealed that fewer than half – 18 out of 42 – of commissioning bodies across England had begun prescribing the drug. This disparity has led to accusations of a “postcode lottery,” where access depends heavily on where a patient lives.
The situation is further complicated by funding allocations. According to freedom of information requests reported by the British Medical Journal (BMJ), few Integrated Care Boards (ICBs) have received sufficient NHS funding to cover even 70% of their eligible patients. This financial constraint directly impacts the number of individuals who can benefit from the medication.
Recognizing the need to accelerate access, the government recently announced a new incentive scheme for GPs, starting in . Practices will receive an average of £3,000 per year in bonuses for prescribing weight loss drugs, with an additional £1,000 for referring patients to weight loss programs. Health Secretary Wes Streeting stated the aim is to ensure access is based on need, not ability to pay, and to curb the rise of private prescriptions and potentially unsafe, unlicensed drugs.
However, some healthcare professionals are skeptical about the effectiveness of the financial incentives. Dr. David Kinsella, speaking to the media, expressed concern that the scheme doesn’t address the fundamental issues. “It’s basically a postcode lottery,”
he said, adding that “There really doesn’t seem to be much good planning in place and quite frankly I don’t see how the surgeries, consultations, can cope with the workload.”
He highlighted the significant time commitment required for proper patient assessment and ongoing monitoring, stating that current rules necessitate two initial consultations lasting 85 minutes each, followed by 20-minute consultations every four weeks, alongside appointments with a dietician.
The workload concerns are significant. GPs currently lack the resources to meet these requirements, according to Dr. Kinsella. “Doctors don’t currently have the resources to meet the requirements,”
he stated. He believes a solution exists, but the NHS system is currently unable to effectively connect the drug’s availability with the necessary support services.
Wegovy, another new generation weight loss drug, is not prescribed by GPs but is instead administered through specialist NHS weight loss services, creating a separate pathway for patients. This two-tiered system further contributes to the complexity of access. Currently, more than one million people in the UK are estimated to be using weight loss injections, with the vast majority – approximately 90% – paying for them privately.
The introduction of these drugs represents a shift in the approach to obesity management. Obesity affects 64.5% of adults in England, and is associated with serious long-term health conditions such as Type 2 diabetes, cardiovascular disease, and certain cancers. The NHS spends approximately £11.4 billion annually treating obesity-related illnesses. While lifestyle interventions, including diet and exercise programs, remain crucial, medications like Mounjaro and Wegovy offer a potentially valuable tool for patients struggling to achieve and maintain a healthy weight.
Despite the challenges, there is a growing recognition of the need to improve access to these medications. The government’s incentive scheme for GPs is a step in that direction, but its ultimate success will depend on addressing the underlying issues of funding, workforce capacity, and logistical coordination. The hope is that by streamlining the process and ensuring equitable distribution, more patients who could benefit from these treatments will be able to access them on the NHS.
The situation remains fluid, and ongoing monitoring of access rates and patient outcomes will be crucial to inform future policy decisions and ensure that these potentially life-changing medications reach those who need them most.